Regorafenib Dose Optimization Study (ReDOS): Randomized phase II trial to evaluate escalating dosing strategy and pre-emptive topical steroids for regorafenib in refractory metastatic colorectal cancer (mCRC) - An ACCRU Network study

T. Bekaii-Saab; F. Ou; D. Anderson; D. Ahn; P. Boland; K. Ciombor; N. Jacobs; R. Desnoyers; J. Cleary; J. Meyers; E. Chiorean; K. Pedersen; A. Barzi; J. Sloan; J. McCune; M. Lacouture; H. Lenz; A. Grothey

doi:10.1093/annonc/mdy149.013

Regorafenib Dose Optimization Study (ReDOS): Randomized phase II trial to evaluate escalating dosing strategy and pre-emptive topical steroids for regorafenib in refractory metastatic colorectal cancer (mCRC) - An ACCRU Network study

T. Bekaii-Saab, F. Ou, D. Anderson, D. Ahn, P. Boland, K. Ciombor, N. Jacobs, R. Desnoyers, J. Cleary, J. Meyers, E. Chiorean, K. Pedersen, A. Barzi, J. Sloan, J. McCune, M. Lacouture, H. Lenz, A. Grothey

Research output: Contribution to journal › Article › peer-review

Original language	English (US)
Pages (from-to)	v105
Journal	Annals of oncology : official journal of the European Society for Medical Oncology
Volume	29
DOIs	https://doi.org/10.1093/annonc/mdy149.013
State	Published - Jun 1 2018

ASJC Scopus subject areas

Hematology
Oncology

Access to Document

10.1093/annonc/mdy149.013

Cite this

Bekaii-Saab, T., Ou, F., Anderson, D., Ahn, D., Boland, P., Ciombor, K., Jacobs, N., Desnoyers, R., Cleary, J., Meyers, J., Chiorean, E., Pedersen, K., Barzi, A., Sloan, J., McCune, J., Lacouture, M., Lenz, H., & Grothey, A. (2018). Regorafenib Dose Optimization Study (ReDOS): Randomized phase II trial to evaluate escalating dosing strategy and pre-emptive topical steroids for regorafenib in refractory metastatic colorectal cancer (mCRC) - An ACCRU Network study. Annals of oncology : official journal of the European Society for Medical Oncology, 29, v105. https://doi.org/10.1093/annonc/mdy149.013

Regorafenib Dose Optimization Study (ReDOS): Randomized phase II trial to evaluate escalating dosing strategy and pre-emptive topical steroids for regorafenib in refractory metastatic colorectal cancer (mCRC) - An ACCRU Network study. / Bekaii-Saab, T.; Ou, F.; Anderson, D. et al.
In: Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, 01.06.2018, p. v105.

Research output: Contribution to journal › Article › peer-review

Bekaii-Saab, T , Ou, F, Anderson, D, Ahn, D, Boland, P, Ciombor, K, Jacobs, N, Desnoyers, R, Cleary, J, Meyers, J, Chiorean, E, Pedersen, K, Barzi, A, Sloan, J, McCune, J, Lacouture, M, Lenz, H & Grothey, A 2018, 'Regorafenib Dose Optimization Study (ReDOS): Randomized phase II trial to evaluate escalating dosing strategy and pre-emptive topical steroids for regorafenib in refractory metastatic colorectal cancer (mCRC) - An ACCRU Network study', Annals of oncology : official journal of the European Society for Medical Oncology, vol. 29, pp. v105. https://doi.org/10.1093/annonc/mdy149.013

Bekaii-Saab T , Ou F, Anderson D, Ahn D, Boland P, Ciombor K et al. Regorafenib Dose Optimization Study (ReDOS): Randomized phase II trial to evaluate escalating dosing strategy and pre-emptive topical steroids for regorafenib in refractory metastatic colorectal cancer (mCRC) - An ACCRU Network study. Annals of oncology : official journal of the European Society for Medical Oncology. 2018 Jun 1;29:v105. doi: 10.1093/annonc/mdy149.013

Bekaii-Saab, T. ; Ou, F. ; Anderson, D. et al. / Regorafenib Dose Optimization Study (ReDOS) : Randomized phase II trial to evaluate escalating dosing strategy and pre-emptive topical steroids for regorafenib in refractory metastatic colorectal cancer (mCRC) - An ACCRU Network study. In: Annals of oncology : official journal of the European Society for Medical Oncology. 2018 ; Vol. 29. pp. v105.

@article{df7b09fb26a442aa9a80d8cee4d2a571,

title = "Regorafenib Dose Optimization Study (ReDOS): Randomized phase II trial to evaluate escalating dosing strategy and pre-emptive topical steroids for regorafenib in refractory metastatic colorectal cancer (mCRC) - An ACCRU Network study",

author = "T. Bekaii-Saab and F. Ou and D. Anderson and D. Ahn and P. Boland and K. Ciombor and N. Jacobs and R. Desnoyers and J. Cleary and J. Meyers and E. Chiorean and K. Pedersen and A. Barzi and J. Sloan and J. McCune and M. Lacouture and H. Lenz and A. Grothey",

year = "2018",

month = jun,

day = "1",

doi = "10.1093/annonc/mdy149.013",

language = "English (US)",

volume = "29",

pages = "v105",

journal = "Annals of oncology : official journal of the European Society for Medical Oncology",

issn = "0923-7534",

publisher = "Elsevier Ltd",

}

TY - JOUR

T1 - Regorafenib Dose Optimization Study (ReDOS)

T2 - Randomized phase II trial to evaluate escalating dosing strategy and pre-emptive topical steroids for regorafenib in refractory metastatic colorectal cancer (mCRC) - An ACCRU Network study

AU - Bekaii-Saab, T.

AU - Ou, F.

AU - Anderson, D.

AU - Ahn, D.

AU - Boland, P.

AU - Ciombor, K.

AU - Jacobs, N.

AU - Desnoyers, R.

AU - Cleary, J.

AU - Meyers, J.

AU - Chiorean, E.

AU - Pedersen, K.

AU - Barzi, A.

AU - Sloan, J.

AU - McCune, J.

AU - Lacouture, M.

AU - Lenz, H.

AU - Grothey, A.

PY - 2018/6/1

Y1 - 2018/6/1

UR - https://www.scopus.com/pages/publications/85081564849

UR - http://www.scopus.com/inward/citedby.url?scp=85081564849&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdy149.013

DO - 10.1093/annonc/mdy149.013

M3 - Article

C2 - 32176993

SN - 0923-7534

VL - 29

SP - v105

JO - Annals of oncology : official journal of the European Society for Medical Oncology

JF - Annals of oncology : official journal of the European Society for Medical Oncology

ER -

Regorafenib Dose Optimization Study (ReDOS): Randomized phase II trial to evaluate escalating dosing strategy and pre-emptive topical steroids for regorafenib in refractory metastatic colorectal cancer (mCRC) - An ACCRU Network study

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this